Compare McCormick & Company, Incorporated (MKC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? McCormick & Company, Incorporated trades at $53.17 (market cap $14.22B), while State Street SPDR S&P Biotech ETF trades at $158.95. The key difference: McCormick & Company, Incorporated pays a 3.63% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, McCormick & Company, Incorporated nearer its low. Which is the better fit depends on your goals.
| MKC | XBI | |
|---|---|---|
Market Cap | $14.22B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $72.26 | $164.28 |
52-Week Low | $45.60 | $86.92 |
Enterprise Value | $18.82B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $53.10, down slightly by 0.06% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion Unilever Foods merger planned for 2027, driving positive sentiment and a consensus price target of $59.67.
MKC presents a compelling investment case with undervalued metrics and strategic growth from the Unilever deal, though risks include integration challenges and soft consumer volumes. Analysts are mixed but lean bullish, with 36.67% buy ratings. The stock offers a solid dividend and upside potential, but investors should monitor merger execution and volume trends.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
